Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015 May. 72 (5):749-58; quiz 759-60. [QxMD MEDLINE Link].
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015 May. 72 (5):761-70; quiz 771-2. [QxMD MEDLINE Link].
Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018 Jan. 78 (1):148-155. [QxMD MEDLINE Link].
Greaves MW, Burova E. Flushing: causes, investigation and clinical consequences. J Eur Acad Dermatol Venereol. 1997. 8:91-100.
Higgins E, du Vivier A. Alcohol intake and other skin disorders. Clin Dermatol. 1999 Jul-Aug. 17(4):437-41. [QxMD MEDLINE Link].
Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005 Feb 24. 352(8):793-803. [QxMD MEDLINE Link].
Bamford JT, Gessert CE, Renier CM. Measurement of the severity of rosacea. J Am Acad Dermatol. 2004 Nov. 51(5):697-703. [QxMD MEDLINE Link].
Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004 Sep. 51(3):327-41; quiz 342-4. [QxMD MEDLINE Link].
Dahl MV. Rosacea subtypes: a treatment algorithm. Cutis. 2004 Sep. 74(3 Suppl):21-7, 32-4. [QxMD MEDLINE Link].
Laquer V, Hoang V, Nguyen A, Kelly KM. Angiogenesis in cutaneous disease: part II. J Am Acad Dermatol. 2009 Dec. 61(6):945-58; quiz 959-60. [QxMD MEDLINE Link].
Bonnar E, Eustace P, Powell FC. The Demodex mite population in rosacea. J Am Acad Dermatol. 1993 Mar. 28(3):443-8. [QxMD MEDLINE Link].
Tisma VS, Basta-Juzbasic A, Jaganjac M, et al. Oxidative stress and ferritin expression in the skin of patients with rosacea. J Am Acad Dermatol. 2009 Feb. 60(2):270-6. [QxMD MEDLINE Link].
Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthetic Derm. Jan 2009. 2(1):26-30.
Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res. 2005 Oct 18. 10(10):454-6. [QxMD MEDLINE Link].
Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2008 Aug. 122(2):261-6. [QxMD MEDLINE Link].
Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018. 7:[QxMD MEDLINE Link].
Aloi F, Tomasini C, Soro E, Pippione M. The clinicopathologic spectrum of rhinophyma. J Am Acad Dermatol. 2000 Mar. 42(3):468-72. [QxMD MEDLINE Link].
Lonne-Rahm S, Nordlind K, Edstrom DW, Ros AM, Berg M. Laser treatment of rosacea: a pathoetiological study. Arch Dermatol. 2004 Nov. 140(11):1345-9. [QxMD MEDLINE Link].
[Guideline] Hampton PJ, Berth-Jones J, Duarte Williamson CE, Hay R, Leslie TA, Porter I, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021 May 15. [QxMD MEDLINE Link]. [Full Text].
van Zuuren EJ, Kramer S, Carter B, Graber MA, Fedorowicz Z. Interventions for rosacea. Cochrane Database Syst Rev. 2011 Mar 16. 3:CD003262. [QxMD MEDLINE Link].
Ceilley RI. Advances in the topical treatment of acne and rosacea. J Drugs Dermatol. 2004 Sep-Oct. 3(5 Suppl):S12-22. [QxMD MEDLINE Link].
Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994 Mar. 130(3):319-24. [QxMD MEDLINE Link].
Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005 May. 19(3):273-85. [QxMD MEDLINE Link].
Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and Safety of Once-Daily Topical Brimonidine Tartrate Gel 0.5% for the Treatment of Moderate to Severe Facial Erythema of Rosacea: Results of Two Randomized, Double-blind, and Vehicle-Controlled Pivotal Studies. J Drugs Dermatol. 2013 Jun 1. 12(6):650-6. [QxMD MEDLINE Link].
Rhofade (oxymetazoline topical) [package insert]. Irvine, Calif: Allergan. January 2017. Available at [Full Text].
Stein L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014 Mar. 13(3):316-23. [QxMD MEDLINE Link].
Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis. 2007 Aug. 80(2):149-51. [QxMD MEDLINE Link].
Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999 Nov. 41(5 Pt 1):775-7. [QxMD MEDLINE Link].
Karincaoglu Y, Bayram N, Aycan O, Esrefoglu M. The clinical importance of demodex folliculorum presenting with nonspecific facial signs and symptoms. J Dermatol. 2004 Aug. 31(8):618-26. [QxMD MEDLINE Link].
Brown M, Hernández-Martín A, Clement A, Colmenero I, Torrelo A. Severe demodexfolliculorum-associated oculocutaneous rosacea in a girl successfully treated with ivermectin. JAMA Dermatol. 2014 Jan. 150(1):61-3. [QxMD MEDLINE Link].
Galderma. Randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study investigating the pharmacodynamics and safety of three concentrations of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), applied in subjects with moderate to severe erythematotelangiectatic rosacea. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT00989014. Accessed: August 21, 2014.
Galderma. A phase 3 randomized, double blind, 12 week vehicle controlled, parallel group study assessing the efficacy and safety of CD5024 1 % cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40 week investigator blinded extension comparing the long term safety of CD5024 1% cream versus azelaic Acid 15 % gel. ClinicalTials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01493687. Accessed: August 21, 2014.
Galderma. Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36-week extension period (ATTRACT). ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/NCT01493947. Accessed: August 21, 2014.
Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007 Mar. 12(2):1-5, 9. [QxMD MEDLINE Link].